Skip to main content

Table 2 Correlation of rheumatoid factor and anti-cyclic citrullinated peptide antibodies with patient characteristics at baseline (week 0)

From: High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study

  RF at week 0 Anti-CCP at week 0
Rho p Value Rho p Value
Sex (0 = male, 1 = female) −0.157 0.0057 −0.043 0.4489
Age 0.154 0.0070 0.106 0.0643
BMI 0.037 0.5141 0.016 0.7863
Disease duration 0.119 0.0368 −0.046 0.4225
NSAID usea −0.006 0.9119 0.022 0.7021
Glucocorticoid usea 0.022 0.6967 0.023 0.6893
DMARD (other than MTX) usea −0.051 0.3727 0.065 0.2549
Duration of MTX use 0.050 0.3832 0.009 0.8687
MTX dose −0.069 0.2256 −0.013 0.8184
Comorbiditya −0.023 0.6874 0.129 0.0240
DAS28-CRP 0.087 0.1278 0.042 0.4596
Total modified Sharp score 0.132 0.0214 −0.019 0.7385
HAQ 0.089 0.1186 0.081 0.1557
MMP-3 −0.129 0.0236 −0.057 0.3198
IL-6 0.069 0.2287 0.040 0.4809
TNF 0.209 0.0002 0.117 0.0413
RF 0.373 <0.0001
Anti-CCP 0.373 <0.0001
  1. Abbreviations: BMI Body mass index, CCP Cyclic citrullinated peptide antibodies, DAS28-CRP Disease Activity Score in 28 joints based on C-reactive protein, HAQ Health Assessment Questionnaire, IL-6 Interleukin-6, MMP-3 Matrix metalloproteinase-3, MTX Methotrexate, NSAID Nonsteroidal anti-inflammatory drug, RF Rheumatoid factor, Rho Spearman’s rank correlation coefficient, TNF Tumor necrosis factor
  2. aCategories of response are 0 = no, 1 = yes